Showing 111-120 of 9351 results for "".
- International Consortium of Mohs Surgery Launches to Support Global Collaboration in Skin Cancer Carehttps://practicaldermatology.com/news/international-consortium-of-mohs-surgery-launches-to-support-global-collaboration-in-skin-cancer-care/2488635/The International Consortium of Mohs Surgery (ICMS) has officially launched as a global professional association focused on advancing Mohs micrographic surgery and cutaneous oncology through education, research, collaboration, and professional exchange. ICMS leadership signed the organizat
- Emblation Names Four Medical Affairs Advisors for SwiftProhttps://practicaldermatology.com/news/emblation-names-four-medical-affairs-advisors-for-swiftpro/2488631/Emblation has appointed four clinicians and podiatry experts as Medical Affairs Advisors to support clinical education initiatives surrounding its SwiftPro microwave therapy system, which the company said recently received US Food and Drug Administration (FDA) 510(k) cleara
- Marie Claire Recognizes ZORYVE for Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/marie-claire-recognizes-zoryve-for-atopic-dermatitis-treatment/2488632/Arcutis Biotherapeutics announced that roflumilast cream 0.15% (ZORYVE) received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, a new category recognizing innovation in prescription dermatologic treatments. The award recognizes ZORYVE f
- Litifilimab Meets Primary Endpoint in Phase 2 Cutaneous Lupus Studyhttps://practicaldermatology.com/news/litifilimab-meets-primary-endpoint-in-phase-2-cutaneous-lupus-study/2488613/Biogen reported positive phase 2 results from Part A of the phase 2/3 AMETHYST study evaluating litifilimab in patients with cutaneous lupus erythematosus (CLE), with the investigational therapy meeting the study’s primary endpoint and showing improvement across several mea
- Phase 2 DLE Trial Meets Primary Endpoint With Daxdilimabhttps://practicaldermatology.com/news/eadv-phase-2-dle-trial-meets-primary-endpoint-with-daxdilimab/2488598/Daxdilimab improved measures of disease activity in adults with moderate-to-severe discoid lupus erythematosus (DLE), according to new data from a phase 2 trial presented at EADV 2026. Researchers included 72 adults aged 18 to 75 years with chronic, treatment-refrac
- Tulisokibart Meets Phase 2b Primary Endpoint in Hidradenitis Suppurativahttps://practicaldermatology.com/news/tulisokibart-meets-phase-2b-primary-endpoint-in-hidradenitis-suppurativa/2488592/Tulisokibart, an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), met the primary endpoint in a Phase 2b trial evaluating the therapy in patients with moderate-to-severe hidradenitis suppurativa (HS), according to results presente
- Science of Skin Summit: AI in Medicine Requires More Than Knowing Which Model Scores Besthttps://practicaldermatology.com/news/science-of-skin-summit-ai-in-medicine-requires-more-than-knowing-which-model-scores-best/2488531/Artificial intelligence models are evolving so rapidly that clinicians may struggle to determine which tools they can trust, but choosing the model that performs best on a standardized test may not provide the answer. Speaking at the Science of Skin Summit, Roxana Daneshjou, MD, PhD, discu
- Science of Skin Urticaria Discussion Highlights Expanding Treatment Options and Need to Measure Disease Controlhttps://practicaldermatology.com/news/science-of-skin-urticaria-discussion-highlights-expanding-treatment-options-and-need-to-measure-disease-control/2488529/The growing treatment armamentarium for chronic spontaneous urticaria (CSU) is giving dermatologists more opportunities to individualize therapy, but effective management begins with fundamentals: selecting and adequately dosing antihistamines, identifyi
- Report: Estimated 4.7 Million Americans Diagnosed With NMSC Annuallyhttps://practicaldermatology.com/news/report-estimated-47-million-americans-diagnosed-with-nmsc-annually/2488474/A new analysis from SkinCure Oncology estimates that 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) each, approximately 42% higher than a commonly cited estimate based on 2012 data.
- Meta-Analysis: IBD Events Are Rare With IL-17 Inhibitors in HShttps://practicaldermatology.com/news/meta-analysis-finds-rare-ibd-events-with-il-17-inhibitors-in-hs/2488443/Interleukin (IL)-17 inhibitors were not associated with a statistically significant increase in inflammatory bowel disease (IBD) risk among patients with hidradenitis suppurativa (HS) in a systematic review and meta-analysis published online in JAMA Dermatology. IBD Events Remain